A Safety and Tolerability Study of ABT-126 in Elderly

A Multiple Dose Study of Safety, Tolerability and Pharmacokinetics of ABT-126 in Elderly Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00867399

Enrollment

Registered

2009-03-23

Start date

2009-03-31

Completion date

Unknown

Last updated

2010-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

The objectives of this study are to assess the safety, tolerability and pharmacokinetics of ABT-126 in elderly subjects.

Interventions

DRUGABT-126

See arm for details

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Healthy male or female subjects 65 years or greater. * Has a MMSE score of 27 or higher.

Exclusion criteria

* History of dementia including by not limited to Alzheimer's disease, Parkinson's disease and mult-infarct dementia. * History of any significant neurological disease. * Has an estimated creatinine clearance \< 30 mL/min

Design outcomes

Primary

Measure	Time frame
Safety and Tolerability Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)	Study Days -1 thru Day 28
Assess the Pharmacokinetics	Study Days -1 thru Day 28

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026